Clinical Trial Update: A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial update for CRV431 in NASH patients with F2-F3 fibrosis; study completed and results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Fibrosis
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• CRV431

Snippet

Sponsor: Hepion Pharmaceuticals, Inc. | Conditions: NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver | Phase 2 | Status: COMPLETED | Results posted: 2022-07-15